Comparison of ribavirin and placebo in CDC group III human immunodeficiency virus infection. Spanish Ribavirin Trial Group.

摘要: To assess the efficacy and safety of ribavirin in patients with human immunodeficiency virus (HIV) infection a multicenter placebo-controlled prospectively randomized trail was conducted CDC group III HIV-infected individuals between February 1988-October 1989. Mean treatment time 39 weeks (range 6-52); 152 were enrolled whom 133 evaluated. The 2 groups similar at baseline 66% all subjects had intravenous drug abuse as main risk factor for HIV infection. Ribavirin given dose 15 mg/kg daily by mouth (average 1000 mg). 9 67 placebo (13.4%) progressed to Groups IVA or D vs. 6 66 (9%) group. Progressions IVC2 7 (10.4%) (13.6%) respectively. These differences are not statistically significant CD4 cell counts total lymphocytes white cells CD4/CD8 ratios during an no clinically important side effects noted. (authors)